<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04118075</url>
  </required_header>
  <id_info>
    <org_study_id>RJH-Lym-2018</org_study_id>
    <nct_id>NCT04118075</nct_id>
  </id_info>
  <brief_title>PT-CY With or Without Low-dose ATG for Lymphoid Malignancies Undergoing Allo-HSCT</brief_title>
  <official_title>Post Transplantation Cyclophosphamide With or Without Low-dose ATG for Patients With Lymphoid Malignancies Undergoing Allogeneic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      All patients received Flu-BU-VP16 as myeloablative conditioning followed by cyclophosphamide
      (D+3 and +4) and subsequent tacrolimus. For patients with unrelated or haplo-donor received
      low-dose ATG at Day +15.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For patients with high-risk lymphoid malignancies, patients will undergo allo-HSCT from HLA
      matched sibling, unrelated (9~10/10) donor or hallo-identical donors. For all patients will
      receive myeloablative conditioning with 5-day fludarabine, 2-day VP-16 and 3-day busulifan.
      For prophylaxis graft versus host disease (GVHD), patients will receive cyclophosphamide
      50mg/kg daily on D+3 and +4 with subsequent tacrolimus starting at D+5. For patients
      receiving HSCT from unrelated or haplo-donor, low-dose ATG 2.5mg/kg will be given on Day +15.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>grade II-IV acute GVHD</measure>
    <time_frame>Day 100</time_frame>
    <description>cumulated incidence of grade II-IV aGVHD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>grade III-IV acute GVHD</measure>
    <time_frame>Day 100</time_frame>
    <description>cumulated incidence of grade III-IV aGVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non relapse mortality (NRM)</measure>
    <time_frame>Day 100</time_frame>
    <description>cumulated incidence of NRM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chronic GVHD (cGVHD)</measure>
    <time_frame>1 year</time_frame>
    <description>cumulated incidence of overall cGVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>moderate to sever chronic GVHD</measure>
    <time_frame>1 year</time_frame>
    <description>cumulated incidence of moderate to severe cGVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse rate</measure>
    <time_frame>1 year</time_frame>
    <description>cumulated incidence of bone marrow or PET/biopsy documented relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non relapse mortality</measure>
    <time_frame>1 year</time_frame>
    <description>cumulated incidence of NRM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>1 year</time_frame>
    <description>overall survival from entry of study to any cause of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GVHD-free relapse free survival (GRFS)</measure>
    <time_frame>1 year</time_frame>
    <description>survival without II-IV aGVHD, moderate to severe cGVHD, relapse or any other death event of any case</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">23</enrollment>
  <condition>GVHD, Acute</condition>
  <arm_group>
    <arm_group_label>PT-CY-FK +/- ATG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GVHD prophylaxis: PT-CY followed by tacrolimus for all patients. low-dose ATG for patients with unrelated or haplo-identical transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PT-CY-FK +/-ATG</intervention_name>
    <description>GVHD prophylaxis: PT-CY followed by tacrolimus for all patients. low-dose ATG for patients with unrelated or haplo-identical transplantation.</description>
    <arm_group_label>PT-CY-FK +/- ATG</arm_group_label>
    <other_name>RJH-Lym-2018</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with lymphoid malignancies: CR1 or CR2 for acute lymphoblastic leukemia; T
             cell lymphoma (any CR/PR); B cell lymphoma (PR1 or CR2), hodgkin's disease (CR2 or
             beyond), Sezary syndrome

          -  patients with HLA matched sibling, unrelated (HLA 9~10/10 matched) or haplo-identical
             donor

        Exclusion Criteria:

          -  patients with active infection

          -  patients with abnormal liver function damage: ALT/AST above 2X normal range

          -  patients with abnormal renal function damage Scr&gt;160µmol/L;

          -  patients with insufficient pulmonary function (FEV1，FVC，DLCO&lt;50%）and heart failure or
             with EF &lt;50%)

          -  patients with mental instability

          -  unwilling to give inform consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiong Hu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ling Wang, M.D</last_name>
    <phone>86-21-64370045</phone>
    <phone_ext>601878</phone_ext>
    <email>cclingjar@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiong Hu</last_name>
    <phone>86-21-64370045</phone>
    <phone_ext>601878</phone_ext>
    <email>hj10709@rjh.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rui Jin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ling Wang</last_name>
      <phone>86-21-64370045</phone>
      <phone_ext>601878</phone_ext>
      <email>cclingjar@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Jiong HU</last_name>
      <phone>86-21-64370045</phone>
      <phone_ext>601878</phone_ext>
      <email>hj10709@rjh.com.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 4, 2019</study_first_submitted>
  <study_first_submitted_qc>October 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2019</study_first_posted>
  <last_update_submitted>April 2, 2020</last_update_submitted>
  <last_update_submitted_qc>April 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jiong HU</investigator_full_name>
    <investigator_title>Head, Blood &amp; Marrow Transplantation Program, Chief physician</investigator_title>
  </responsible_party>
  <keyword>aGVHD, cGVHD, PT-CY</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

